13F filer · CIK 1601086
ARMISTICE CAPITAL, LLC
NEW YORK, NY · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$8.2B
+$2.5B vs prior
Positions
333
New / sold out
172 / 100
Added / reduced
73 / 68
Turnover
15.2%
buys $2.5B · sells $1.0B
Top-10 weight
61.5%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | SPYSTATE STR SPDR S&P 500 ETF TPUT | +1,100,000 | +52.4% | +$821.4M |
| Added | ISHARES TRPUT | +2,300,000 | +65.7% | +$691.0M |
| Added | CYTOKINETICS INC | +436,804 | +57.1% | +$37.2M |
| Added | SUPERNUS PHARMACEUTICALS | +750,854 | +39.6% | +$34.9M |
| Added | REGENERON PHARMACEUTICALS | +53,683 | +148.6% | +$33.5M |
| Added | SANOFI SA | +764,000 | +254.7% | +$32.6M |
| New | TRAVERE THERAPEUTICS INCCALL | +500,000 | – | +$28.4M |
| New | WATERS CORP | +75,004 | – | +$28.1M |
| New | MINERALYS THERAPEUTICS INCCALL | +1,040,000 | – | +$28.1M |
| Added | INCYTE CORP | +243,188 | +37.0% | +$27.6M |
235 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | TRAVERE THERAPEUTICS INC | -3,324,878 | -67.9% | $-188.9M |
| Reduced | PTC THERAPEUTICS INC | -1,003,054 | -48.4% | $-81.8M |
| Reduced | IMMUNOVANT INC | -1,828,916 | -51.3% | $-70.5M |
| Reduced | DATADOG INC | -170,885 | -81.9% | $-44.5M |
| Reduced | NEUROCRINE BIOSCIENCES INC | -188,162 | -26.0% | $-31.7M |
| Sold out | AVANOS MED INC | -2,000,000 | -100.0% | $-28.0M |
| Reduced | HUMANA INC | -68,752 | -48.7% | $-27.3M |
| Reduced | IMMUNOVANT INCCALL | -700,000 | -36.8% | $-27.0M |
| Sold out | MEDLINE INC | -564,857 | -100.0% | $-25.1M |
| Sold out | KALVISTA PHARMACEUTICALS INC | -1,236,000 | -100.0% | $-24.9M |
158 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | SPYSTATE STR SPDR S&P 500 ETF TPUT | 3,200,000 | $2.4B | 29.24% |
| 2 | ISHARES TRPUTRUSSELL 2000 ETF | 5,800,000 | $1.7B | 21.32% |
| 3 | MADRIGAL PHARMACEUTICALS INCCOM | 288,000 | $154.6M | 1.89% |
| 4 | CYTOKINETICS INCCALLCOM NEW | 1,530,000 | $130.3M | 1.59% |
| 5 | SUPERNUS PHARMACEUTICALSCOM | 2,646,201 | $123.1M | 1.51% |
| 6 | AGIOS PHARMACEUTICALS INCCALLCOM | 2,810,000 | $104.3M | 1.28% |
| 7 | CYTOKINETICS INCCOM NEW | 1,201,342 | $102.3M | 1.25% |
| 8 | INCYTE CORPCOM | 900,005 | $102.0M | 1.25% |
| 9 | NEUROCRINE BIOSCIENCES INCCOM | 535,838 | $90.3M | 1.10% |
| 10 | TRAVERE THERAPEUTICS INCCOM | 1,572,539 | $89.3M | 1.09% |
323 more rows. Subscribe for $29/month to see every row, download the data and use the API.